Adam Brufsky to Humans
This is a "connection" page, showing publications Adam Brufsky has written about Humans.
Connection Strength
0.189
-
Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. Int J Biol Macromol. 2021 Jun 30; 181:801-809.
Score: 0.008
-
Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano. 2021 05 25; 15(5):8069-8086.
Score: 0.008
-
Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. Expert Opin Pharmacother. 2021 Jun; 22(8):947-952.
Score: 0.007
-
Urgent Need for Field Surveys of Coronaviruses in Southeast Asia to Understand the SARS-CoV-2 Phylogeny and Risk Assessment for Future Outbreaks. Biomolecules. 2021 03 09; 11(3).
Score: 0.007
-
Questions concerning the proximal origin of SARS-CoV-2. J Med Virol. 2021 03; 93(3):1204-1206.
Score: 0.007
-
Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. J Med Virol. 2021 04; 93(4):2396-2405.
Score: 0.007
-
Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features. Molecules. 2020 Dec 13; 25(24).
Score: 0.007
-
Viewpoint: Origin of SARS-CoV-2. Viruses. 2020 10 22; 12(11).
Score: 0.007
-
Potential interventions for SARS-CoV-2 infections: Zinc showing promise. J Med Virol. 2021 03; 93(3):1201-1203.
Score: 0.007
-
Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med. 2020 06 29; 18(1):261.
Score: 0.007
-
Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. J Med Virol. 2020 Sep; 92(9):1386-1390.
Score: 0.007
-
DC/L-SIGNs of hope in the COVID-19 pandemic. J Med Virol. 2020 Sep; 92(9):1396-1398.
Score: 0.007
-
Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. J Med Virol. 2020 11; 92(11):2379-2380.
Score: 0.007
-
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol. 2020 07; 92(7):770-775.
Score: 0.007
-
A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. Sci Rep. 2019 10 16; 9(1):14863.
Score: 0.007
-
CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019 10; 20(10):1329-1330.
Score: 0.007
-
Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use? Breast J. 2019 01; 25(1):7-8.
Score: 0.006
-
Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Nov; 23(6):718-722.
Score: 0.006
-
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017 Sep; 59:22-32.
Score: 0.006
-
TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017 07; 18(7):843-845.
Score: 0.006
-
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncol. 2017 04; 18(4):428-429.
Score: 0.006
-
Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol. 2016 09; 17(9):1175-6.
Score: 0.005
-
SARS-CoV-2 research using human pluripotent stem cells and organoids. Stem Cells Transl Med. 2021 11; 10(11):1491-1499.
Score: 0.002
-
The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. Autoimmun Rev. 2021 10; 20(10):102909.
Score: 0.002
-
COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street? Biomolecules. 2021 07 13; 11(7).
Score: 0.002
-
A unique view of SARS-CoV-2 through the lens of ORF8 protein. Comput Biol Med. 2021 06; 133:104380.
Score: 0.002
-
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med. 2020 12 30; 21(4):517-530.
Score: 0.002
-
The structural basis of accelerated host cell entry by SARS-CoV-2†. FEBS J. 2021 09; 288(17):5010-5020.
Score: 0.002
-
Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol. 2021 01; 93(1):409-415.
Score: 0.002
-
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020 Jan; 23(1):37-47.
Score: 0.002
-
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Res Treat. 2019 Jul; 176(2):321-328.
Score: 0.002
-
Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes. Histopathology. 2018 Oct; 73(4):692-700.
Score: 0.002
-
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Breast Cancer. 2018 12; 18(6):e1239-e1245.
Score: 0.002
-
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018 09 01; 36(25):2621-2629.
Score: 0.002
-
Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 31; 150(1):34-42.
Score: 0.002
-
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. Oncol Nurs Forum. 2018 05 01; 45(3):308-326.
Score: 0.002
-
Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 07; 149(4):332-343.
Score: 0.002
-
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 02 01; 110(2).
Score: 0.002
-
Alcohol consumption and breast tumor gene expression. Breast Cancer Res. 2017 Sep 12; 19(1):108.
Score: 0.001
-
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 08; 30(8):1078-1085.
Score: 0.001
-
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017 Aug; 164(3):649-658.
Score: 0.001
-
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10; 35(23):2647-2655.
Score: 0.001
-
Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017 06 01; 123(11):2061-2069.
Score: 0.001
-
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. Cancer Med. 2017 02; 6(2):339-348.
Score: 0.001
-
Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015 Aug 01; 121(15):2627-36.
Score: 0.001
-
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20.
Score: 0.001
-
Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med. 2006 Oct; 130(10):1516-21.
Score: 0.001